Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach (483 views)
Eur J Med Chem (ISSN: 0223-5234, 1768-3254, 1768-3254electronic), 2013 Mar; 61: 116-121.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.432, 5-year impact factor: 4.071
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84874934514&partnerID=40&md5=2a345ef714f77a95323ded4be2a91e0d
Keywords: Fluorescence Study, Her2 Receptor, Receptor Fragment Model, Selective Ligands, Epidermal Growth Factor Receptor 2, Trastuzumab, Article, Cancer Therapy, Controlled Study, Dissociation, Drug Delivery System, Fluorescence Analysis, Human, Titrimetry, Antibodies, Monoclonal, Humanized, Crystallography, X-Ray, Dose-Response Relationship, Enzyme Inhibitors, Molecular, Molecular Structure, Peptides, Erbb-2, Spectrometry, Structure-Activity Relationship,
Affiliations:
*** IBB - CNR ***
Institute of Biostructures and Bioimages, National Research Council, Via Mezzocannone 16, 80138 Naples, Italy
Department of Chemistry and Biochemistry, University of Colorado, Boulder, 80309 CO, United States
Institute of Crystallography, CNR, 70126 Bari, Italy
References:
Yarden, Y., Sliwkowski, M.X., (2001) Nat. Rev. Mol. Cell. Biol., 2, pp. 127-13
Lax, I., Burgess, W.H., Bellot, F., Ullrich, A., Schlessinger, J., Givol, D., (1988) Mol. Cell Biol., 8, pp. 1831-1834
Pietras, R.J., Arboleda, J., Reese, D.M., Wongvipat, N., Pegram, M.D., Ramos, L., Gorman, C.M., Slamon, D.J., (1995) Oncogene, 10, pp. 2435-2446
Garrett, T.P., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., Lovrecz, G.O., Kofler, M., Ward, C.W., (2003) Mol. Cell., 11, pp. 495-505
Niehans, G.A., Singleton, T.P., Dykoski, D., Kiang, D.T., (1993) J. Natl. Cancer Inst., 85, pp. 1230-1235
Neve, R.M., Lane, H.A., Hynes, N.E., (2001) Ann. Oncol., 12 (SUPPL. 1), pp. 9-S13
Engel, R.H., Kaklamani, V.G., (2007) Drugs, 67 (9), pp. 1329-1341
Faltus, T., Yuan, J., Zimmer, B., Krämer, A., Loibl, S., Kaufmann, M., Strebhardt, K., (2004) Neoplasia, 6 (6), pp. 786-795
Yang, G., Qi Cai, K., Thompson-Lanza, J.A., Bast, Jr.R.C., Liu, J., (2004) J. Biol. Chem., 279 (6), pp. 4339-4345
Pils, D., Pinter, A., Reibenwein, J., Alfanz, A., Horak, P., Schmid, B.C., Hefler, L., Krainer, M., (2007) Br. J. Cancer, 96 (3), pp. 485-491
Roh, H., Pippin, J., Drebin, J.A., (2000) Cancer Res., 60 (3), pp. 560-565
Tai, W., Qin, B., Cheng, K., (2010) Mol. Pharmaceutics, 7 (2), pp. 543-556
Sakai, K., Mori, S., Kawamoto, T., Taniguchi, S., Kobori, O., Morioka, Y., Kuroki, T., Kano, K., (1986) J. Natl. Cancer Inst., 77 (5), pp. 1047-1052
Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kiimini, H., Ohoyama, S., Miyazaki, I., Sasaki, T., (1991) Cancer Res., 51 (3), pp. 1034-1038
Bookman, M.A., Darcy, K.M., Clarke-Pearson, D., Boothby, R.A., Horowitzet, I.R., (2003) J. Clin. Oncol., 21 (2), pp. 283-290
Steffensen, K.D., Waldstrøm, M., Jeppeseny, U., Jakobsen, E., Brandslundk, I., Jakobsen, A., (2007) Int. J. Gynecol. Cancer, 17 (4), pp. 798-807
Hellstrom, I., Goodman, G., Pullman, J., Yang, Y., Hellström, K.E., (2001) Cancer Res., 61 (6), pp. 2420-2423
Juhl, H., Downing, S.G., Wellstein, A., Czubayko, F., (1997) J. Biol. Chem., 272 (47), pp. 29482-29486
Tan, A.R., Swain, S.M., (2003) Semin. Oncol., 30, pp. 54-64
Pegram, M.D., Reese, D.M., (2002) Semin. Oncol., 29 (3 SUPPL. 11), pp. 29-37
Pegram, M., Chan, D., Dichmann, R.A., (2006) Breast Cancer Res. Treat., 100 (SUPPL. 1), pp. 28-S29
Agus, D.B., Gordon, M.S., Taylor, C., Natale, R.B., Karlan, B., Mendelson, D.S., Press, M.F., Fyfe, G., (2005) J. Clin. Oncol., 23 (11), pp. 2534-2543
Spector, N., Xia, W., El-Hariry, I., Yarden, Y., Bacus, S., (2007) Breast Cancer Res., 9, p. 205
Tai, W., Mahato, R., Cheng, K., (2010) J. Controlled Release, 146, pp. 264-275
Landon, L.A., Deutscher, S.L., (2003) J. Cell. Biochem., 90, pp. 509-517
Karasseva, N.G., Glinsky, V.V., Chen, N.X., Komatireddy, R., Quinn, T.P., (2002) J. Protein Chem., 4, pp. 287-296
Kumar, S.R., Quinn, T.Q., Deutscher, S.L., (2007) Clin. Cancer Res., 13, pp. 6070-6079
Xiao, N., Cheng, D., Wang, Y., Chen, L., Liu, X., Dou, S., Liu, G., Rusckowski, M., (2011) Cancer Biol. Ther., 11, pp. 22-31
Monfregola, L., Vitale, R.M., Amodeo, P., De Luca, S., (2009) Bioorg. Med. Chem., 17, pp. 7015-7020
Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W., Leahy, D.J., (2003) Nature, 421, pp. 756-760
Ragone, R., De Luca, S., Tesauro, D., Pedone, C., Morelli, G., (2001) Biopolymers, 56, pp. 47-53
De Luca, S., Sanseverino, M., Zocchi, I., Pedone, C., Morelli, G., Ragone, R., (2005) Biopolymers, 77, pp. 205-211
De Luca, S., Ragone, R., Bracco, C., Digilio, G., Aloj, L., Tesauro, D., Saviano, M., Morelli, G., (2003) Chembiochem, 4, pp. 1176-1187
De Luca, S., Saviano, M., Lassiani, L., Yannakopoulou, K., Stefanidou, P., Aloj, L., Morelli, G., Varnavas, A., (2006) J. Med. Chem., 49, pp. 2456-2462
Edelhoch, H., (1967) Biochemistry, 6, pp. 1948-1954
Pace, C.N., Vajdos, F., Fee, L., Grimsley, G., Gray, T., (1995) Protein Sci., 4, pp. 2411-2423
Gill, S.C., Von Hippel, P.H., (1989) Anal. Biochem., 182, pp. 319-326
Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Slamon, D. J., (1995) Oncogene, 10, pp. 2435-2446
Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Ward, C. W., (2003) Mol. Cell., 11, pp. 495-505
Niehans, G. A., Singleton, T. P., Dykoski, D., Kiang, D. T., (1993) J. Natl. Cancer Inst., 85, pp. 1230-1235
Neve, R. M., Lane, H. A., Hynes, N. E., (2001) Ann. Oncol., 12 (SUPPL. 1), pp. 9-S13
Engel, R. H., Kaklamani, V. G., (2007) Drugs, 67 (9), pp. 1329-1341
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., Horowitzet, I. R., (2003) J. Clin. Oncol., 21 (2), pp. 283-290
Steffensen, K. D., Waldstr m, M., Jeppeseny, U., Jakobsen, E., Brandslundk, I., Jakobsen, A., (2007) Int. J. Gynecol. Cancer, 17 (4), pp. 798-807
Tan, A. R., Swain, S. M., (2003) Semin. Oncol., 30, pp. 54-64
Pegram, M. D., Reese, D. M., (2002) Semin. Oncol., 29 (3 SUPPL. 11), pp. 29-37
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Fyfe, G., (2005) J. Clin. Oncol., 23 (11), pp. 2534-2543
Landon, L. A., Deutscher, S. L., (2003) J. Cell. Biochem., 90, pp. 509-517
Karasseva, N. G., Glinsky, V. V., Chen, N. X., Komatireddy, R., Quinn, T. P., (2002) J. Protein Chem., 4, pp. 287-296
Kumar, S. R., Quinn, T. Q., Deutscher, S. L., (2007) Clin. Cancer Res., 13, pp. 6070-6079
Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., Leahy, D. J., (2003) Nature, 421, pp. 756-760
Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., Gray, T., (1995) Protein Sci., 4, pp. 2411-2423
Gill, S. C., Von Hippel, P. H., (1989) Anal. Biochem., 182, pp. 319-326
Eur J Med Chem (ISSN: 0223-5234, 1768-3254, 1768-3254electronic), 2013 Mar; 61: 116-121.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.432, 5-year impact factor: 4.071
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84874934514&partnerID=40&md5=2a345ef714f77a95323ded4be2a91e0d
Keywords: Fluorescence Study, Her2 Receptor, Receptor Fragment Model, Selective Ligands, Epidermal Growth Factor Receptor 2, Trastuzumab, Article, Cancer Therapy, Controlled Study, Dissociation, Drug Delivery System, Fluorescence Analysis, Human, Titrimetry, Antibodies, Monoclonal, Humanized, Crystallography, X-Ray, Dose-Response Relationship, Enzyme Inhibitors, Molecular, Molecular Structure, Peptides, Erbb-2, Spectrometry, Structure-Activity Relationship,
Affiliations:
*** IBB - CNR ***
Institute of Biostructures and Bioimages, National Research Council, Via Mezzocannone 16, 80138 Naples, Italy
Department of Chemistry and Biochemistry, University of Colorado, Boulder, 80309 CO, United States
Institute of Crystallography, CNR, 70126 Bari, Italy
References:
Yarden, Y., Sliwkowski, M.X., (2001) Nat. Rev. Mol. Cell. Biol., 2, pp. 127-13
Lax, I., Burgess, W.H., Bellot, F., Ullrich, A., Schlessinger, J., Givol, D., (1988) Mol. Cell Biol., 8, pp. 1831-1834
Pietras, R.J., Arboleda, J., Reese, D.M., Wongvipat, N., Pegram, M.D., Ramos, L., Gorman, C.M., Slamon, D.J., (1995) Oncogene, 10, pp. 2435-2446
Garrett, T.P., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., Lovrecz, G.O., Kofler, M., Ward, C.W., (2003) Mol. Cell., 11, pp. 495-505
Niehans, G.A., Singleton, T.P., Dykoski, D., Kiang, D.T., (1993) J. Natl. Cancer Inst., 85, pp. 1230-1235
Neve, R.M., Lane, H.A., Hynes, N.E., (2001) Ann. Oncol., 12 (SUPPL. 1), pp. 9-S13
Engel, R.H., Kaklamani, V.G., (2007) Drugs, 67 (9), pp. 1329-1341
Faltus, T., Yuan, J., Zimmer, B., Krämer, A., Loibl, S., Kaufmann, M., Strebhardt, K., (2004) Neoplasia, 6 (6), pp. 786-795
Yang, G., Qi Cai, K., Thompson-Lanza, J.A., Bast, Jr.R.C., Liu, J., (2004) J. Biol. Chem., 279 (6), pp. 4339-4345
Pils, D., Pinter, A., Reibenwein, J., Alfanz, A., Horak, P., Schmid, B.C., Hefler, L., Krainer, M., (2007) Br. J. Cancer, 96 (3), pp. 485-491
Roh, H., Pippin, J., Drebin, J.A., (2000) Cancer Res., 60 (3), pp. 560-565
Tai, W., Qin, B., Cheng, K., (2010) Mol. Pharmaceutics, 7 (2), pp. 543-556
Sakai, K., Mori, S., Kawamoto, T., Taniguchi, S., Kobori, O., Morioka, Y., Kuroki, T., Kano, K., (1986) J. Natl. Cancer Inst., 77 (5), pp. 1047-1052
Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kiimini, H., Ohoyama, S., Miyazaki, I., Sasaki, T., (1991) Cancer Res., 51 (3), pp. 1034-1038
Bookman, M.A., Darcy, K.M., Clarke-Pearson, D., Boothby, R.A., Horowitzet, I.R., (2003) J. Clin. Oncol., 21 (2), pp. 283-290
Steffensen, K.D., Waldstrøm, M., Jeppeseny, U., Jakobsen, E., Brandslundk, I., Jakobsen, A., (2007) Int. J. Gynecol. Cancer, 17 (4), pp. 798-807
Hellstrom, I., Goodman, G., Pullman, J., Yang, Y., Hellström, K.E., (2001) Cancer Res., 61 (6), pp. 2420-2423
Juhl, H., Downing, S.G., Wellstein, A., Czubayko, F., (1997) J. Biol. Chem., 272 (47), pp. 29482-29486
Tan, A.R., Swain, S.M., (2003) Semin. Oncol., 30, pp. 54-64
Pegram, M.D., Reese, D.M., (2002) Semin. Oncol., 29 (3 SUPPL. 11), pp. 29-37
Pegram, M., Chan, D., Dichmann, R.A., (2006) Breast Cancer Res. Treat., 100 (SUPPL. 1), pp. 28-S29
Agus, D.B., Gordon, M.S., Taylor, C., Natale, R.B., Karlan, B., Mendelson, D.S., Press, M.F., Fyfe, G., (2005) J. Clin. Oncol., 23 (11), pp. 2534-2543
Spector, N., Xia, W., El-Hariry, I., Yarden, Y., Bacus, S., (2007) Breast Cancer Res., 9, p. 205
Tai, W., Mahato, R., Cheng, K., (2010) J. Controlled Release, 146, pp. 264-275
Landon, L.A., Deutscher, S.L., (2003) J. Cell. Biochem., 90, pp. 509-517
Karasseva, N.G., Glinsky, V.V., Chen, N.X., Komatireddy, R., Quinn, T.P., (2002) J. Protein Chem., 4, pp. 287-296
Kumar, S.R., Quinn, T.Q., Deutscher, S.L., (2007) Clin. Cancer Res., 13, pp. 6070-6079
Xiao, N., Cheng, D., Wang, Y., Chen, L., Liu, X., Dou, S., Liu, G., Rusckowski, M., (2011) Cancer Biol. Ther., 11, pp. 22-31
Monfregola, L., Vitale, R.M., Amodeo, P., De Luca, S., (2009) Bioorg. Med. Chem., 17, pp. 7015-7020
Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W., Leahy, D.J., (2003) Nature, 421, pp. 756-760
Ragone, R., De Luca, S., Tesauro, D., Pedone, C., Morelli, G., (2001) Biopolymers, 56, pp. 47-53
De Luca, S., Sanseverino, M., Zocchi, I., Pedone, C., Morelli, G., Ragone, R., (2005) Biopolymers, 77, pp. 205-211
De Luca, S., Ragone, R., Bracco, C., Digilio, G., Aloj, L., Tesauro, D., Saviano, M., Morelli, G., (2003) Chembiochem, 4, pp. 1176-1187
De Luca, S., Saviano, M., Lassiani, L., Yannakopoulou, K., Stefanidou, P., Aloj, L., Morelli, G., Varnavas, A., (2006) J. Med. Chem., 49, pp. 2456-2462
Edelhoch, H., (1967) Biochemistry, 6, pp. 1948-1954
Pace, C.N., Vajdos, F., Fee, L., Grimsley, G., Gray, T., (1995) Protein Sci., 4, pp. 2411-2423
Gill, S.C., Von Hippel, P.H., (1989) Anal. Biochem., 182, pp. 319-326
Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Slamon, D. J., (1995) Oncogene, 10, pp. 2435-2446
Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Ward, C. W., (2003) Mol. Cell., 11, pp. 495-505
Niehans, G. A., Singleton, T. P., Dykoski, D., Kiang, D. T., (1993) J. Natl. Cancer Inst., 85, pp. 1230-1235
Neve, R. M., Lane, H. A., Hynes, N. E., (2001) Ann. Oncol., 12 (SUPPL. 1), pp. 9-S13
Engel, R. H., Kaklamani, V. G., (2007) Drugs, 67 (9), pp. 1329-1341
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., Horowitzet, I. R., (2003) J. Clin. Oncol., 21 (2), pp. 283-290
Steffensen, K. D., Waldstr m, M., Jeppeseny, U., Jakobsen, E., Brandslundk, I., Jakobsen, A., (2007) Int. J. Gynecol. Cancer, 17 (4), pp. 798-807
Tan, A. R., Swain, S. M., (2003) Semin. Oncol., 30, pp. 54-64
Pegram, M. D., Reese, D. M., (2002) Semin. Oncol., 29 (3 SUPPL. 11), pp. 29-37
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Fyfe, G., (2005) J. Clin. Oncol., 23 (11), pp. 2534-2543
Landon, L. A., Deutscher, S. L., (2003) J. Cell. Biochem., 90, pp. 509-517
Karasseva, N. G., Glinsky, V. V., Chen, N. X., Komatireddy, R., Quinn, T. P., (2002) J. Protein Chem., 4, pp. 287-296
Kumar, S. R., Quinn, T. Q., Deutscher, S. L., (2007) Clin. Cancer Res., 13, pp. 6070-6079
Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., Leahy, D. J., (2003) Nature, 421, pp. 756-760
Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., Gray, T., (1995) Protein Sci., 4, pp. 2411-2423
Gill, S. C., Von Hippel, P. H., (1989) Anal. Biochem., 182, pp. 319-326
Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach
Fluorescence titrations allowed us to study the interaction process between Herceptin (Fab)-derived peptides and a synthetic peptide mimicking a subdomain IV of the receptor HER2 (HER2-DIVMP). For some of the investigated peptide/HER2-DIVMP complexes a nanomolar dissociation constant was found. The performed interaction studies were completely immune from interferences of other receptor domains not covered by the design, thus decreasing the possibilities of selecting potential ligands able to bind other subtypes of HER2 receptor family. Our results demonstrate that the adopted receptor fragment approach represents an efficient methodology for selecting new molecules as lead structures specific for the receptor target. For these reasons the optimized compounds could be employed as delivery agents for the receptor-mediated anticancer therapy. (C) 2012 Elsevier Masson SAS. All rights reserved.
Fluorescence titrations allowed us to study the interaction process between Herceptin (Fab)-derived peptides and a synthetic peptide mimicking a subdomain IV of the receptor HER2 (HER2-DIVMP). For some of the investigated peptide/HER2-DIVMP complexes a nanomolar dissociation constant was found. The performed interaction studies were completely immune from interferences of other receptor domains not covered by the design, thus decreasing the possibilities of selecting potential ligands able to bind other subtypes of HER2 receptor family. Our results demonstrate that the adopted receptor fragment approach represents an efficient methodology for selecting new molecules as lead structures specific for the receptor target. For these reasons the optimized compounds could be employed as delivery agents for the receptor-mediated anticancer therapy. (C) 2012 Elsevier Masson SAS. All rights reserved.
Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach
Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach
Other filter: ([btitle,keywords] "Fluorescence Study" ...
De Luca S, Verdoliva V, Saviano M
* Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives (54 views)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print), 2020 Dec 24; 63(24): 15333-15343.
Impact Factor: 6.205
View Export to BibTeX Export to EndNote
De Luca S, Verdoliva V, Saviano M, Fattorusso R, Diana D
* SPR and NMR characterization of the molecular interaction between A9 peptide and a model system of HER2 receptor: A fragment approach for selecting peptide structures specific for their target (135 views)
J Pept Sci (ISSN: 1075-2617linking, 1099-1387electronic), 2020 Feb; 26(2): e3231-e3231.
Impact Factor: 1.877
View Export to BibTeX Export to EndNote
Langella E, Calce E, Saviano M, De Luca S
* Structural identification of an HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach (310 views)
Mol Biosyst (ISSN: 1742-206x), 2016 Jun 21; 12(7): 2159-2167.
Impact Factor: 2.781
View Export to BibTeX Export to EndNote
Calce E, Saviano M, De Luca S
* Development of Targeting Ligands for HER2 Receptor: Simplified Receptor Model Employed for Selecting Highly Specific Molecules (261 views)
International Journal Of Peptide Research And Therapeutics, 2015 Dec; N/D: N/D-N/D.
Impact Factor: 0.99
View Export to BibTeX Export to EndNote
Calce E, Monfregola L, Saviano M, De Luca S
* HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor (572 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2015 May 20; 22(21): 2525-2538.
Impact Factor: 3.455
View Export to BibTeX Export to EndNote
Calce E, Sandomenico A, Saviano M, Ruvo M, De Luca S
* Cysteine Co-Oxidation Process Driven By Native Peptide Folding: An Example On Her2 Receptor Model System (369 views)
Amino Acids (ISSN: 0939-4451, 1438-2199, 1438-2199electronic), 2014; 46(5): 1197-1206.
Impact Factor: 3.293
View Export to BibTeX Export to EndNote
Avitabile C, Moggio L, Malgieri G, Capasso D, Di Gaetano S, Saviano M, Pedone C, Romanelli A
* Gamma Sulphate Pna (pna S): Highly Selective Dna Binding Molecule Showing Promising Antigene Activity (451 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2012 May 7; 7(5): e35774-e35774.
Impact Factor: 3.73
View Export to BibTeX Export to EndNote
Folgiero V, Di Carlo SE, Bossi G, Spugnini E, Di Benedetto A, Bon G, Milella M, Fabi A, Accardo A, Morelli G, Mottolese M, Falcioni R
* Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells (519 views)
Cell Death & (ISSN: 2041-4889, 2041-4889electronic), 2012; 3(12): N/D-N/D.
Impact Factor: 6.044
View Export to BibTeX Export to EndNote
Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, Sica F, Pucci P, D'Alessio G, De Lorenzo C
* A novel ErbB2 epitope targeted by human antitumor immunoagents (403 views)
Febs Journal (ISSN: 1742-464x), 2011 Apr; 278(7): 1156-1166.
Impact Factor: 3.79
View Export to BibTeX Export to EndNote
Monfregola L, Vitale RM, Amodeo P, De Luca S
* A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: A proof of concept on HER2 receptor (425 views)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 1464-3391electronic), 2009 Oct 1; 17(19): 7015-7020.
Impact Factor: 2.822
View Export to BibTeX Export to EndNote
Insabato L, Amelio I, Quarto M, Zannetti A, Tolino F, De Mauro G, Cerchia L, Riccio P, Baumhoer D, Condorelli G, Terracciano L, De Franciscis V
* Elevated Expression of the Tyrosine Phosphatase SHP-1 Defines a Subset of High-Grade Breast Tumors (449 views)
Oncology (ISSN: 0030-2414), 2009; 77(6): 378-384.
Impact Factor: 2.112
View Export to BibTeX Export to EndNote
De Luca S, Sanseverino M, Zocchi I, Pedone C, Morelli G, Ragone R
* Receptor fragment approach to the binding between CCK8 peptide and cholecystokinin receptors: A fluorescence study on type B receptor fragment CCKB-R (352-379) (371 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2005 Mar; 77(4): 205-211.
Impact Factor: 2.545
View Export to BibTeX Export to EndNote
* Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives (54 views)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print), 2020 Dec 24; 63(24): 15333-15343.
Impact Factor: 6.205
View Export to BibTeX Export to EndNote
De Luca S, Verdoliva V, Saviano M, Fattorusso R, Diana D
* SPR and NMR characterization of the molecular interaction between A9 peptide and a model system of HER2 receptor: A fragment approach for selecting peptide structures specific for their target (135 views)
J Pept Sci (ISSN: 1075-2617linking, 1099-1387electronic), 2020 Feb; 26(2): e3231-e3231.
Impact Factor: 1.877
View Export to BibTeX Export to EndNote
Langella E, Calce E, Saviano M, De Luca S
* Structural identification of an HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach (310 views)
Mol Biosyst (ISSN: 1742-206x), 2016 Jun 21; 12(7): 2159-2167.
Impact Factor: 2.781
View Export to BibTeX Export to EndNote
Calce E, Saviano M, De Luca S
* Development of Targeting Ligands for HER2 Receptor: Simplified Receptor Model Employed for Selecting Highly Specific Molecules (261 views)
International Journal Of Peptide Research And Therapeutics, 2015 Dec; N/D: N/D-N/D.
Impact Factor: 0.99
View Export to BibTeX Export to EndNote
Calce E, Monfregola L, Saviano M, De Luca S
* HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor (572 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2015 May 20; 22(21): 2525-2538.
Impact Factor: 3.455
View Export to BibTeX Export to EndNote
Calce E, Sandomenico A, Saviano M, Ruvo M, De Luca S
* Cysteine Co-Oxidation Process Driven By Native Peptide Folding: An Example On Her2 Receptor Model System (369 views)
Amino Acids (ISSN: 0939-4451, 1438-2199, 1438-2199electronic), 2014; 46(5): 1197-1206.
Impact Factor: 3.293
View Export to BibTeX Export to EndNote
Avitabile C, Moggio L, Malgieri G, Capasso D, Di Gaetano S, Saviano M, Pedone C, Romanelli A
* Gamma Sulphate Pna (pna S): Highly Selective Dna Binding Molecule Showing Promising Antigene Activity (451 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2012 May 7; 7(5): e35774-e35774.
Impact Factor: 3.73
View Export to BibTeX Export to EndNote
Folgiero V, Di Carlo SE, Bossi G, Spugnini E, Di Benedetto A, Bon G, Milella M, Fabi A, Accardo A, Morelli G, Mottolese M, Falcioni R
* Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells (519 views)
Cell Death & (ISSN: 2041-4889, 2041-4889electronic), 2012; 3(12): N/D-N/D.
Impact Factor: 6.044
View Export to BibTeX Export to EndNote
Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, Sica F, Pucci P, D'Alessio G, De Lorenzo C
* A novel ErbB2 epitope targeted by human antitumor immunoagents (403 views)
Febs Journal (ISSN: 1742-464x), 2011 Apr; 278(7): 1156-1166.
Impact Factor: 3.79
View Export to BibTeX Export to EndNote
Monfregola L, Vitale RM, Amodeo P, De Luca S
* A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: A proof of concept on HER2 receptor (425 views)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 1464-3391electronic), 2009 Oct 1; 17(19): 7015-7020.
Impact Factor: 2.822
View Export to BibTeX Export to EndNote
Insabato L, Amelio I, Quarto M, Zannetti A, Tolino F, De Mauro G, Cerchia L, Riccio P, Baumhoer D, Condorelli G, Terracciano L, De Franciscis V
* Elevated Expression of the Tyrosine Phosphatase SHP-1 Defines a Subset of High-Grade Breast Tumors (449 views)
Oncology (ISSN: 0030-2414), 2009; 77(6): 378-384.
Impact Factor: 2.112
View Export to BibTeX Export to EndNote
De Luca S, Sanseverino M, Zocchi I, Pedone C, Morelli G, Ragone R
* Receptor fragment approach to the binding between CCK8 peptide and cholecystokinin receptors: A fluorescence study on type B receptor fragment CCKB-R (352-379) (371 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2005 Mar; 77(4): 205-211.
Impact Factor: 2.545
View Export to BibTeX Export to EndNote
12 Records (10 excluding Abstracts).
Total impact factor: 39.644 (29.87 excluding Abstracts).
Total 5 year impact factor: 38.676 (28.388 excluding Abstracts).
Total impact factor: 39.644 (29.87 excluding Abstracts).
Total 5 year impact factor: 38.676 (28.388 excluding Abstracts).
483 views. Last view on Saturday 27 May 2023, 22:51:43
ibb.cnr.it
